FDA ax­es di­ag­nos­tic re­quire­ment for Lil­ly's Verzenio + en­docrine ther­a­py in cer­tain breast can­cer pa­tients

In the fall of 2021, when the FDA first au­tho­rized Eli Lil­ly’s CD4/6 in­hibitor Verzenio plus en­docrine ther­a­py in ear­ly-stage HR-pos­i­tive, HER2-neg­a­tive breast can­cer and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER